This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aveo Fires 140 Workers As Punishment For CEO's Incompetence

CAMBRIDGE, Mass. ( TheStreet) -- Aveo Oncology (AVEO - Get Report) fired 140 middle and lower-level employees -- 62 percent of its workforce -- on Tuesday in order to save money to pay the salaries and bonuses of its top executives who blew up the company, decimated shareholder value and are too cowardly to accept responsibility for their incompetence.

At Aveo, accountability starts at the bottom.

"This is an incredibly sad day for Aveo," said CEO Tuan Ha-Ngoc on Wednesday's conference call.

True, but certainly not so sad for Ha-Ngoc since he keeps his job, his $567,875 per year salary, bonus and other perks. Ha-Ngoc was in charge of Aveo when it conducted a poorly designed phase III trial for the kidney cancer drug tivozanib. He was in charge when FDA raised concerns about the tivozanib study and recommended the company run another one. Ha-Ngoc kept this information from investors and ignored the FDA's advice.

Last month, an FDA advisory panel excoriated the tivozanib data and told FDA to reject the drug, sending Aveo shares plummeting by more than 60 percent. Under Ha-Ngoc's watch.

FDA is expected to follow through on the negative advice of the panel and reject tivozanib next month, Aveo concedes, which is why 140 employees have now been fired.

But Ha-Ngoc keeps his job.

"Tuan did not offer his resignation to the board. The company doesn't discuss conversations that took place in the board room, only outcomes," said Aveo spokesman Dan Budwick, when asked if Aveo's board ever considered making changes to the management team.

Only a single Aveo executive, Chief Operating Office Elan Ezickson, is leaving the company, and he's being allowed to resign nicely. Ezickson made $1 million last year.

Last week, Aveo Chairman Henri Termeer assured me that there would be "severe consequences" for the company stemming from the failure of tivozanib.

Am I surprised that Aveo's rank-and-file employees are bearing the brunt of this colossal cock-up?

No, of course not. When you're Termeer, Ha-Ngoc or one their C-level cronies, "sad days" in biotech are only for the schmoes who work for a living.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AVEO $0.93 -3.63%
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs